Served as lead counsel in representing Biotest AG (Biotest), a German publicly traded biotechnology company, in signing a global License, Development and Commercialization Agreement with Abbott Laboratories for the further development and commercialization of Biotest’s BT-061, a novel anti-CD4 antibody for the treatment of Rheumatoid Arthritis (RA) and psoriasis. In connection with the deal, Biotest will receive an upfront payment of $85 million, and upon completion of certain milestones, additional payments totaling $395 million, plus royalties.

Experience Center

Match our Experience to Your Needs

Experience Highlights

Integration of Atlanta Cardiology Group P.C. into Piedmont Heart Institute, a subsidiary of the Piedmont Healthcare System
Represented Atlanta Cardiology Group P.C. with its integration from a large multi-office cardiology practice into Piedmont Heart more
Advising a Fortune 100 subsidiary in pension fund's multibillion dollar investments
Represents the wholly-owned subsidiary of a major Fortune 100 company that acts as the in-house asset manager in connection with the pension more
Settlement of a major title insurance claim for a 54 acre development project
Served as lead counsel representing the developer of a high profile, 54 acre project in a major title insurance claim arising out of an easement more
Zino Davidoff S.A. v. CVS Corp.
Obtained a preliminary injunction, which was affirmed on appeal, enjoining CVS's sale of decoded gray market DAVIDOFF COOL WATER fragrances, as well more